Advanced search
Publication Cover
Expert Opinion on Drug Safety Volume 7, 2008 - Issue 5
Submit an article Journal homepage
159
Views
14
CrossRef citations to date
0
Altmetric
Review

The safety of rosiglitazone in the treatment of Type 2 diabetes

Sonal Singh Assistant Professor Wake Forest University School of Medicine, Department of Medicine, Winston-Salem, NC 27103, USA; Wake Forest University School of Medicine, One Medical Center Boulevard, Section on General Internal Medicine, Winston-Salem, NC 27157, USA +1 336 716 8203; +1 336 716 7359; [email protected]
, MD MPH &
Yoon K Loke Senior Lecturer in Clinical Pharmacology University of East Anglia, School of Medicine, Norwich, UK
, MBBS MD
Pages 579-585 | Published online: 01 Sep 2008

Citations (14)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Amit Agrawal. (2009) Effectiveness of the Early Addition of Rosiglitazone to Control Hyperglycemia after Unsuccessful Submaximal Sulphonylurea Monotherapy: The Rosiglitazone Early versus SULphonylurea Titration (RESULT) Study. The Physician and Sportsmedicine 37:1, pages 146-148.
Read now

Articles from other publishers (13)

Enca Martin-Rendon. (2016) Meta-Analyses of Human Cell-Based Cardiac Regeneration TherapiesResponse to Martin-Rendon. Circulation Research 118:8, pages 1264-1272.
Crossref
Richard G. BachMaria Mori BrooksManuel LombarderoSaul GenuthThomas W. DonnerAlan GarberLaurence KennedyE. Scott MonradRodica Pop-BusuiSheryl F. KelseyRobert L. Frye. (2013) Rosiglitazone and Outcomes for Patients With Diabetes Mellitus and Coronary Artery Disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. Circulation 128:8, pages 785-794.
Crossref
Hyun-Il Yang, Woo Sik Kim, Dal-Hyun Kim & Jin Seok Kang. (2013) Histopathological Evaluation of Heart Toxicity of a Novel Selective PPAR-? Agonists CKD-501 in db/db Mice. Biomolecules and Therapeutics 21:1, pages 84-88.
Crossref
Cristina M. Sena, Carla F. Bento, Paulo Pereira, Filipa Marques & Raquel Seiça. 2013. New Strategies to Advance Pre/Diabetes Care: Integrative Approach by PPPM. New Strategies to Advance Pre/Diabetes Care: Integrative Approach by PPPM 29 87 .
Zhouji Chen, Patrick A. Vigueira, Kari T. Chambers, Angela M. Hall, Mayurranjan S. Mitra, Nathan Qi, William G. McDonald, Jerry R. Colca, Rolf F. Kletzien & Brian N. Finck. (2012) Insulin Resistance and Metabolic Derangements in Obese Mice Are Ameliorated by a Novel Peroxisome Proliferator-activated Receptor γ-sparing Thiazolidinedione. Journal of Biological Chemistry 287:28, pages 23537-23548.
Crossref
Zafar H Israili. (2011) Advances in the Treatment of Type 2 Diabetes Mellitus. American Journal of Therapeutics 18:2, pages 117-152.
Crossref
Jing-bin Huang, Ying-long Liu, Pei-wu Sun, Xiao-dong Lv, Kong Bo & Xiang-ming Fan. (2010) Novel Strategy for Treatment of Pulmonary Arterial Hypertension: Enhancement of Apoptosis. Lung 188:3, pages 179-189.
Crossref
Nicholas Michael Morton. (2010) Obesity and corticosteroids: 11β-Hydroxysteroid type 1 as a cause and therapeutic target in metabolic disease. Molecular and Cellular Endocrinology 316:2, pages 154-164.
Crossref
Cristina M. Sena, Carla F. Bento, Paulo Pereira & Raquel Seiça. (2010) Diabetes mellitus: new challenges and innovative therapies. EPMA Journal 1:1, pages 138-163.
Crossref
Hong Li, Ran Cui, Haidong Cai, Guoting Wu, Zhongwei Lv, Chunjun Sheng, Xiaoyun Cheng, Fang Li & Yongchun Yu. (2009) The effect of thiazolidinediones on bone mineral density in Chinese older patients with type 2 diabetes. Journal of Bone and Mineral Metabolism 28:1, pages 77-81.
Crossref
James S. Floyd, Elizabeth Barbehenn, Peter Lurie & Sidney M. Wolfe. (2009) Case series of liver failure associated with rosiglitazone and pioglitazone. Pharmacoepidemiology and Drug Safety 18:12, pages 1238-1243.
Crossref
Michael Bodmer, Christian Meier, Marius E. Kraenzlin & Christoph R. Meier. (2009) Risk of Fractures with Glitazones. Drug Safety 32:7, pages 539-547.
Crossref
Carole Fogg, Rachna Kasliwal & Saad A.W. Shakir. (2009) Risk Management and Outcomes of Adverse Events to Pioglitazone in Primary Care in the UK. Drug Safety 32:3, pages 229-237.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.